Show simple item record

dc.contributor.editorL. Pouliquen, Daniel
dc.contributor.editorKopecka, Joanna
dc.date.accessioned2022-01-11T13:50:24Z
dc.date.available2022-01-11T13:50:24Z
dc.date.issued2021
dc.identifierONIX_20220111_9783036523682_878
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/77046
dc.description.abstractMalignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many concerns in public health given its late diagnosis, dismal prognosis, and lack of current efficient therapies.To deal with this situation, important breakthroughs have recently been made in the understanding of MM’s complex biology and the carcinogenic process of the different patterns of the disease. Examples of these include the development of new biomarkers and the deciphering of gene–environment interactions, molecular mechanisms of invasiveness, deregulated pathways, altered expression of miRNAs, DNA damage repair, or metabolic profile. From now on, MM’s aggressive and chemoresistant character appears linked to a polyclonal malignancy, and heterogeneity in molecular alterations.Given these improvements, new therapeutic targets are being explored to solve the double challenge faced by clinicians. The first is to reduce tumor development and its wasting consequences as soon as possible, without resistance and with limited toxicity. The second is to stimulate the recognition of tumor cells by the induction of a specific immune response. This Special Issue will highlight all these aspects.
dc.languageEnglish
dc.subject.classificationbic Book Industry Communication::M Medicine
dc.subject.otherwell-differentiated papillary mesothelioma
dc.subject.otherWDPM
dc.subject.othermalignant mesothelioma
dc.subject.otherDNA sequencing
dc.subject.othermutation
dc.subject.othermesothelioma
dc.subject.othertumor suppressor
dc.subject.othertargeted therapy
dc.subject.otherimmunotherapy
dc.subject.otherbiomarkers
dc.subject.otherproteomics
dc.subject.othermacrophage-capping protein
dc.subject.otherfatty acid-binding protein
dc.subject.otherlaminin subunit beta-2
dc.subject.otherselenium-binding protein 1
dc.subject.othercarcinogenesis
dc.subject.othermalignant pleural mesothelioma
dc.subject.otherasbestos exposure
dc.subject.otherDNA methylation
dc.subject.otherlymphocyte-to-monocyte ratio
dc.subject.otherepigenome-wide analysis
dc.subject.othersurvival analysis
dc.subject.othermetabolomics
dc.subject.otherradiotherapy
dc.subject.othercancers
dc.subject.otherinflammation
dc.subject.otherinfiltrating immune cells
dc.subject.otherprognostic biomarker
dc.subject.otherpredictive biomarker
dc.subject.otherimmune therapy
dc.subject.otherVATS
dc.subject.otherextrapleural pneumonectomy
dc.subject.otherpleurectomy decortication
dc.subject.othertherapy response
dc.subject.othersurvival
dc.subject.otherFDG
dc.subject.otherPET-CT
dc.subject.othermesothelium
dc.subject.otheroxidative stress
dc.subject.otherredox-sensitive factors
dc.subject.otherasbestos
dc.subject.othercarbon nanotubes
dc.subject.otherprotein-protein interactions
dc.subject.othersystems biology
dc.subject.othernetwork analysis
dc.subject.otherdrug repurposing
dc.subject.otherpleural mesothelioma
dc.subject.othergene expression
dc.subject.otherimmunogenicity
dc.subject.othersarcomatoid
dc.subject.otherepithelioid
dc.subject.otherfirst line
dc.subject.othermeta-analysis
dc.subject.othersystematic review
dc.subject.otherMPM
dc.subject.otherlurbinectedin
dc.subject.otherDNA damage response
dc.subject.otherhistotype
dc.subject.otherHippo pathway
dc.subject.otherNF2
dc.subject.otherBAP1
dc.subject.otherCDKN2A
dc.subject.otherPTCH1
dc.subject.otherSETD2
dc.subject.otherMTAP
dc.subject.otherliquid biopsies
dc.subject.othercirculating tumor DNA
dc.subject.otherplasma
dc.subject.othercancer-specific mutations
dc.subject.othergenomics
dc.subject.othercancer biomarkers
dc.subject.othertumor microenvironment
dc.subject.othertumor-associated macrophages
dc.subject.otherdendritic cells
dc.subject.otherimmunohistochemistry
dc.subject.otherinteraction analysis
dc.subject.otherpleural effusion
dc.subject.othern/a
dc.titleMalignant Mesothelioma
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-2367-5
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036523682
oapen.relation.isbn9783036523675
oapen.pages328
oapen.place.publicationBasel, Switzerland


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/